Cargando…

Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis

BACKGROUND: Differences in cytokine/chemokine profiles among patients with neuromyelitis optica (NMO), relapsing remitting multiple sclerosis (RRMS), and primary progressive MS (PPMS), and the relationships of these profiles with clinical and neuroimaging features are unclear. A greater understandin...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsushita, Takuya, Tateishi, Takahisa, Isobe, Noriko, Yonekawa, Tomomi, Yamasaki, Ryo, Matsuse, Dai, Murai, Hiroyuki, Kira, Jun-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630114/
https://www.ncbi.nlm.nih.gov/pubmed/23637915
http://dx.doi.org/10.1371/journal.pone.0061835
_version_ 1782266658315829248
author Matsushita, Takuya
Tateishi, Takahisa
Isobe, Noriko
Yonekawa, Tomomi
Yamasaki, Ryo
Matsuse, Dai
Murai, Hiroyuki
Kira, Jun-ichi
author_facet Matsushita, Takuya
Tateishi, Takahisa
Isobe, Noriko
Yonekawa, Tomomi
Yamasaki, Ryo
Matsuse, Dai
Murai, Hiroyuki
Kira, Jun-ichi
author_sort Matsushita, Takuya
collection PubMed
description BACKGROUND: Differences in cytokine/chemokine profiles among patients with neuromyelitis optica (NMO), relapsing remitting multiple sclerosis (RRMS), and primary progressive MS (PPMS), and the relationships of these profiles with clinical and neuroimaging features are unclear. A greater understanding of these profiles may help in differential diagnosis. METHODS/PRINCIPAL FINDINGS: We measured 27 cytokines/chemokines and growth factors in CSF collected from 20 patients with NMO, 26 with RRMS, nine with PPMS, and 18 with other non-inflammatory neurological diseases (OND) by multiplexed fluorescent bead-based immunoassay. Interleukin (IL)-17A, IL-6, CXCL8 and CXCL10 levels were significantly higher in NMO patients than in OND and RRMS patients at relapse, while granulocyte-colony stimulating factor (G-CSF) and CCL4 levels were significantly higher in NMO patients than in OND patients. In NMO patients, IL-6 and CXCL8 levels were positively correlated with disability and CSF protein concentration while IL-6, CXCL8, G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IFN-γ were positively correlated with CSF neutrophil counts at the time of sample collection. In RRMS patients, IL-6 levels were significantly higher than in OND patients at the relapse phase while CSF cell counts were negatively correlated with the levels of CCL2. Correlation coefficients of cytokines/chemokines in the relapse phase were significantly different in three combinations, IL-6 and GM-CSF, G-CSF and GM-CSF, and GM-CSF and IFN-γ, between RRMS and NMO/NMOSD patients. In PPMS patients, CCL4 and CXCL10 levels were significantly higher than in OND patients. CONCLUSIONS: Our findings suggest distinct cytokine/chemokine alterations in CSF exist among NMO, RRMS and PPMS. In NMO, over-expression of a cluster of Th17- and Th1-related proinflammatory cytokines/chemokines is characteristic, while in PPMS, increased CCL4 and CXCL10 levels may reflect on-going low grade T cell and macrophage/microglia inflammation in the central nervous system. In RRMS, only a mild elevation of proinflammatory cytokines/chemokines was detectable at relapse.
format Online
Article
Text
id pubmed-3630114
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36301142013-05-01 Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis Matsushita, Takuya Tateishi, Takahisa Isobe, Noriko Yonekawa, Tomomi Yamasaki, Ryo Matsuse, Dai Murai, Hiroyuki Kira, Jun-ichi PLoS One Research Article BACKGROUND: Differences in cytokine/chemokine profiles among patients with neuromyelitis optica (NMO), relapsing remitting multiple sclerosis (RRMS), and primary progressive MS (PPMS), and the relationships of these profiles with clinical and neuroimaging features are unclear. A greater understanding of these profiles may help in differential diagnosis. METHODS/PRINCIPAL FINDINGS: We measured 27 cytokines/chemokines and growth factors in CSF collected from 20 patients with NMO, 26 with RRMS, nine with PPMS, and 18 with other non-inflammatory neurological diseases (OND) by multiplexed fluorescent bead-based immunoassay. Interleukin (IL)-17A, IL-6, CXCL8 and CXCL10 levels were significantly higher in NMO patients than in OND and RRMS patients at relapse, while granulocyte-colony stimulating factor (G-CSF) and CCL4 levels were significantly higher in NMO patients than in OND patients. In NMO patients, IL-6 and CXCL8 levels were positively correlated with disability and CSF protein concentration while IL-6, CXCL8, G-CSF, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IFN-γ were positively correlated with CSF neutrophil counts at the time of sample collection. In RRMS patients, IL-6 levels were significantly higher than in OND patients at the relapse phase while CSF cell counts were negatively correlated with the levels of CCL2. Correlation coefficients of cytokines/chemokines in the relapse phase were significantly different in three combinations, IL-6 and GM-CSF, G-CSF and GM-CSF, and GM-CSF and IFN-γ, between RRMS and NMO/NMOSD patients. In PPMS patients, CCL4 and CXCL10 levels were significantly higher than in OND patients. CONCLUSIONS: Our findings suggest distinct cytokine/chemokine alterations in CSF exist among NMO, RRMS and PPMS. In NMO, over-expression of a cluster of Th17- and Th1-related proinflammatory cytokines/chemokines is characteristic, while in PPMS, increased CCL4 and CXCL10 levels may reflect on-going low grade T cell and macrophage/microglia inflammation in the central nervous system. In RRMS, only a mild elevation of proinflammatory cytokines/chemokines was detectable at relapse. Public Library of Science 2013-04-18 /pmc/articles/PMC3630114/ /pubmed/23637915 http://dx.doi.org/10.1371/journal.pone.0061835 Text en © 2013 Matsushita et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Matsushita, Takuya
Tateishi, Takahisa
Isobe, Noriko
Yonekawa, Tomomi
Yamasaki, Ryo
Matsuse, Dai
Murai, Hiroyuki
Kira, Jun-ichi
Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
title Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
title_full Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
title_fullStr Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
title_full_unstemmed Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
title_short Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
title_sort characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630114/
https://www.ncbi.nlm.nih.gov/pubmed/23637915
http://dx.doi.org/10.1371/journal.pone.0061835
work_keys_str_mv AT matsushitatakuya characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis
AT tateishitakahisa characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis
AT isobenoriko characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis
AT yonekawatomomi characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis
AT yamasakiryo characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis
AT matsusedai characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis
AT muraihiroyuki characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis
AT kirajunichi characteristiccerebrospinalfluidcytokinechemokineprofilesinneuromyelitisopticarelapsingremittingorprimaryprogressivemultiplesclerosis